The cGAS-STING pathway is important for the induction of type I IFNs and effective antitumor immunity.21 Intratumoral or intraperitoneal delivery of a murine STING agonist DMXAA resulted in tumor regression.54 Based on this success, intratumoral administration of the human STING agonist (MK-1454, Merck) entered clinical trials (clinicaltrials.gov identifier: NCT 03010176). The gene discussed is STING1; the disease is neoplasm.